Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma

Oncology Letters

Volumn 3, Issue 5, 2012, Pages 990-994

  Kubota, Kei ^a   Tamura, Taiji ^a   Aoyama, Nobutaka ^a   Nogami, Munenobu ^a   Hamada, Norihiko ^a   Nishioka, Akihito ^a   Ogawa, Yasuhiro ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

Contrast material; Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; Hepatocellular carcinoma; Liver function; Magnetic resonance imaging; References

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GADOXETIC ACID; INDOCYANINE GREEN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; IMAGE ENHANCEMENT; INFORMED CONSENT; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER INJURY; LIVER PARENCHYMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

EID: 84857959627     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.629     Document Type: Article

References (35)

1. Hamm B, Staks T, Muhler A, et al: Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195: 785-792, 1995.
2. Vogl TJ, Kummel S, Hammerstingl R, et al: Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200: 59-67, 1996.
3. Reimer P, Rummeny EJ, Shamsi K, et al: Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199: 177-183, 1996.
4. Reimer P, Rummeny EJ, Daldrup HE, et al: Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 7: 275-280, 1997.
5. Stern W, Schick F, Kopp AF, et al: Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41: 255-262, 2000.
6. Huppertz A, Balzer T, Blakeborough A, et al: Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230: 266-275, 2004.
7. Bluemke DA, Sahani D, Amendola M, et al: Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 237: 89-98, 2005.
8. Huppertz A, Haraida S, Kraus A, et al: Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 234: 468-478, 2005.
9. Zech CJ, Grazioli L, Breuer J, Reiser MF and Schoenberg SO: Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43: 504-511, 2008.
10. Hammerstingl R, Huppertz A, Breuer J, et al: Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18: 457-467, 2008.
11. Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ and Weinmann HJ: Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7: 126-132, 1997.
12. Asbach P, Warmuth C, Stemmer A, et al: High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocyte-specific contrast medium. Invest Radiol 43: 809-815, 2008.
13. Clement O, Muhler A, Vexlar V, Berthezene Y and Brasch RC: Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 27: 612-619, 1992.
14. Muhler A, Freise CE, Kuwatsuru R, et al: Acute liver rejection: evaluation with cell-directed MR contrast agents in a rat transplantation model. Radiology 186: 139-146, 1993.
15. Muhler A, Heinzelmann I and Weinmann HJ: Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol 29: 213-216, 1994.
16. Schmitz SA, Muhler A, Wagner S and Wolf KJ: Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol 31: 154-160, 1996.
17. Kim T, Murakami T, Hasuike Y, et al: Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 7: 683-688, 1997.
18. Ryeom HK, Kim SH, Kim JY, et al: Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol 5: 231-239, 2004.
19. Makuuchi M, Kokudo N, Arii S, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 33: 37-51, 2008.
20. Clement O, Muhler A, Vexler VS, et al: Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents. Radiology 185: 163-168, 1992.
21. Kaplowitz N: Physiological significance of glutathione S-trans-ferases. Am J Physiol 239: G439-G444, 1980.
22. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ and Speck U: Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183: 59-64, 1992.
23. Kwon AH, Ha-Kawa SK, Uetsuji S, Inoue T, Matsui Y and Kamiyama Y: Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy. Hepatology 25: 426-429, 1997.
24. Lau H, Man K, Fan ST, Yu WC, Lo CM and Wong J: Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 84: 1255-1259, 1997.
25. Shimizu J, Dono K, Gotoh M, et al: Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 44: 1330-1337, 1999.
26. Tsuda N, Okada M and Murakami T: Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42: 242-247, 2007.
27. Ono M and Saibara T: Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J Gastroenterol 41: 725-732, 2006.
28. Shimada M, Hashimoto E, Taniai M, et al: Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37: 154-160, 2002.
29. Asanuma T, Ono M, Kubota K, et al: Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut 59: 258-266, 2010.
30. Saadeh S, Younossi ZM, Remer EM, et al: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745-750, 2002.
31. Murata Y, Ogawa Y, Saibara T, et al: Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: Determination of a suitable biopsy site for diagnosis. Oncol Rep 10: 97-100, 2003.
32. Kubota K, Hisa N, Fujiwara Y, Fukumoto M, Yoshida D and Yoshida S: Evaluation of the intratumoral vasculature of hepatocellular carcinoma by power Doppler sonography: advantages and disadvantages versus conventional color Doppler sonography. Abdom Imaging 25: 172-178, 2000.
33. Kubota K, Hisa N, Nishikawa T, Ohnishi T, Ogawa Y and Yoshida S: The utility of tissue harmonic imaging in the liver: A comparison with conventional gray-scale sonography. Oncol Rep 7: 767-771, 2000.
34. Kubota K, Hisa N, Nishikawa T, et al: Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 26: 184-190, 2001.
35. Kubota K, Yamanishi T, Itoh S, et al: Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncol Rep 24: 727-732, 2010.